Cyagen Biosciences and Vivo Bio Tech partner to provide easy access to Genomic Technologies to Indian Biomedical R&D.

Santa Clara, USA and Hyderabad, India, Thursday, September 1, 2016 – Cyagen Biosciences a leader in custom animal models and molecular biology tools and Vivo Bio Tech, a preclinical Contract Research Organization and Specific Pathogen Free Laboratory Animal Commercial Breeder, announced that they have entered into an agreement under which Vivo Bio Tech is appointed as the Authorized Distributor of Cyagen Biosciences’ complete product and service portfolio in India.

Through this partnership, the Indian Biomedical Scientists would have an easy access to cost-effective custom-designed and disease-specific genetically engineered rodent models at a short turnaround time to accelerate their research programs.

“We are excited to announce our new partnership with Vivo Bio Tech, a pioneer in the introduction of locally bred Specific Pathogen Free Laboratory Rodents in India. While Cyagen's clientele span the globe in over fifteen countries including India, this new partnership aims to assist Indian researchers in streamlining and advancing their research by increasing the availability of high quality custom designed animal models, custom vectors, and virus packaging service with highly competitive pricing, fast turnaround time, and excellent customer service” said Cyagen Biosciences Chairman of the Board, Mr. Lance Han.

“We are quite excited to partner with Cyagen Biosciences, one of the leading genomics company with innovative technologies like Turboknockout® - the fastest turnaround for ES-cell based gene targeting and with a track record of successfully delivering more than 2,000 transgenic projects and with a clientele in excess of 300 premier universities and companies worldwide. This partnership takes us yet another step forward towards Vivo Bio Tech’s mission to provide Indian Biomedical Scientists easy access to world class research tools and innovative technologies” said Vivo Bio Tech President Dr. A. Sankaranarayanan.

Vivo Bio Tech will distribute Cyagen’s Animal Models - TurboKnockout® Gene Targeting Mice, Transgenic Rodents, Genome Editing Knockout and Knockin Rodents, PiggyBac Transgenic Mice, Transgenic Mouse Embryos, and Cell & Media products, and Vector building & Packaging Services in India. Vivo Bio Tech shall also offer Custom Breeding and Contract Research Services using Cyagen’s Rodent Models.

About Cyagen Biosciences, Inc. Cyagen Biosciences is a CRO and cell culture product manufacturer headquartered in Silicon Valley, California, and with offices in Germany and China. The company is the world's largest provider of custom-designed transgenic and knockout mouse services with shortest turn-around time, a leader in molecular biology tools and manufacturer of research-use stem cells and related culture reagents. The company’s proprietary new technology, Turboknockout® - an ES cell mediated service provides customers with conditional knockout, reporter knockin and humanization mouse models in as little as 6-8 months.

About Vivo Bio Tech Ltd. Vivo Bio Tech is a Hyderabad based public listed CRO offering services to biomedical industry worldwide in the areas of in-vitro / in-vivo toxicology, pharmacological investigations, analytical and physico-chemical testing. The company is also the largest supplier of locally bred Specific Pathogen Free laboratory rodents in India. The company’s state-of-art 125,000 Sq.ft. preclinical research facility is NGCMA OECD-GLP certified and AAALACi accredited.

For Media Inquiries
Cyagen Biosciences, Inc.
Dr. Austin Jelcick
Director of Marketing
P. +1-800-921-8930

Vivo Bio Tech Ltd.
Mr. Kalyan Korisapati
COO & Head – BD
P. +91-8454-244-555


“Vivo Bio to provide international quality lab animals in partnership with Taconic”

Provides Local Researchers with Access to Valuable Animal Models

Hudson, New York and Hyderabad, India, February 6, 2013 – Taconic, a leading provider of life sciences solutions, and Vivo Bio Tech Ltd., a full-service contract research organization, announced they have entered into an agreement under which Vivo Bio Tech will gain rights to breed and distribute select Taconic mouse and rat models in India. Through this arrangement, the two companies will greatly improve the availability of high-quality animals for biomedical researchin India.

The pharmaceutical and biotechnology industry in India is growing at an estimated rate of 12 percent and 20 percent annually – through a combination of new in-house drug development projects and collaboration with western companies – making it a hub for biomedical innovation. The Indian CRO industry is estimated to grow at a CAGR of 31 percent to reach USD 3 billion by the year 2015.

“One of the greatest obstacles to drug discovery in the region is the lack of a local supply of quality laboratory animals,” noted Todd Little, Taconic President and CEO. “Together, Taconic and Vivo Bio Tech will address that challenge by significantly improving investigators’ access to animal models that are proven to be highly valuable to biomedical research, yet unavailable in the local market.”

“With access to high-quality lab animal models from a world leader in the field, Vivo Bio Tech is poised to become the preferred provider of research animal models and contract research services in the rapidly growing pharmaceutical and biotechnology markets in India,” said Vivo Bio Tech Chief Executive Officer Dr. A. Sankaranarayanan.

Vivo Bio Tech will breed and distribute select Taconic animal models, including a variety of inbred and outbred mice and rats, as well as the proprietary Taconic Knockout Repository of more than 4,000 knockout lines, .

“The Taconic Knockout Repository eliminates the time traditionally required for model design and development, which can speed drug development for investigators in the region,” Mr. Little said. The agreement gives the Indian pharmaceutical &biotech research community access to Taconic’s advanced scientific services, including model derivation, cryopreservation, genotyping, health assessment, and custom model generation.

All local breeding will be done at Vivo Bio Tech’s 125,000-square-foot pre-clinical research facility in Andhra Pradesh, India. The facility is accredited by AAALAC (Association for Assessment and Accreditation of Laboratory Animal Care) and registered with CPCSEA (Committee for the Purpose of Control and Supervision of Experiments on Animals) for breeding and commercialization of Murine Pathogen Free™ (MPF™) animals. Throughout the breeding process, Vivo Bio Tech’s highly qualified and well-trained staff will follow Taconic’s rigorous standard operating procedures to ensure quality and integrity.

About Vivo Bio Tech Ltd.
Vivo Bio Tech (based in Andhra Pradesh, India) is a full service CRO offering drug development and discovery services to pharmaceutical and biotech companies worldwide in accordance with OECD-GLP, and AAALAC guidelines. The company offers services in the areas of in-vitro, in-vivo, toxicity studies, pharmacological investigations, pharmacokinetic and toxicokinetic studies.

About Taconic
Taconic is an industry leader providing life science solutions to researchers worldwide for more than 60 years. Taconic accelerates drug discovery by providing fast, convenient access to a full suite of more than 4,000 off-the-shelf in vivo mouse and rat models, as well as custom designed models. Taconic provides study-ready cohorts, including tissue or genetically humanized models, supported by reliable data that can advance early development work. Our scientific expertise, innovative technology and breeding services, enables researchers to confidently partner with Taconic for their entire spectrum of in vivo resource needs. Additional information about Taconic is available at

For Taconic media inquiries:
Susan Fogt
Marketing Communications

For Vivo Bio Tech Ltd inquiries:
Kalyan Kumar Korisapati
Business Development


  • Vivo Bio Tech preclinical research facility received ‘Full Accreditation’ by AAALAC International.


  • Commenced operations of 125,000 Sq.ft preclinical research facility – Small Animals (Rats, Mice, Rabbits, Hamsters and Guinea Pigs)


  • Appointed Dr. A Sankaranarayanan, Ph.D., F.C.P. as Chief Executive Officer and Whole Time Director of the company
  • Received SEZ gazette notification from Government of India, for the company’s land (10.93 hectares) at Pregnapur for developing biotech specific Special Economic Zone vide No. F.1/139/2007


Secured status of Research Establishment vide No. TU/1VRD/2740/2007 from The Department of Scientific & Industrial Research (DSIR), Ministry of Science & Technology, Govt. of India for its custom research facility


Secured status of Research Establishment vide No. 1117/C/07/CPCSEA from the Ministry of Environment & Forests, Govt. of India for its preclinical research facility